<div id="readability-page-1"><p>ADC Therapeutics SA (NYSE:ADCT - Get Free Report) has been given a consensus rating of &#34;Moderate Buy&#34; by the five analysts that are presently  covering the firm, MarketBeat reports. One research analyst  has rated the stock with a sell rating and four have assigned  a buy rating to  the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $7.3333.</p><div><p><span></span><span>Get <strong>ADC Therapeutics</strong> alerts:</span></p></div><p>ADCT has been the subject of a number of recent research reports. Wall Street Zen raised ADC Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 15th. Royal Bank Of Canada  reaffirmed an &#34;outperform&#34; rating and issued a $5.00 price objective on shares of ADC Therapeutics in a research note on Wednesday, December 3rd. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of ADC Therapeutics in a report on Wednesday, January 21st. Finally, Guggenheim  reiterated a &#34;buy&#34; rating and set a $10.00 target price on shares of ADC Therapeutics in a research report on Wednesday, November 12th.</p><p><b>Check Out Our Latest Analysis on ADCT</b></p><h2>Institutional Trading of ADC Therapeutics</h2><p>A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Engineers Gate Manager LP acquired a new position in  ADC Therapeutics during the 4th quarter worth about $43,000.  AQR Capital Management LLC raised its position in shares of  ADC Therapeutics by 42.2% during the fourth quarter. AQR Capital Management LLC now owns 206,576 shares of the company's stock worth $729,000 after acquiring an additional 61,324 shares during the last quarter.  Cantor Fitzgerald L. P. bought a new position in shares of  ADC Therapeutics during the fourth quarter worth about $353,000.  Jump Financial LLC lifted its stake in shares of  ADC Therapeutics by 1,299.8% in the fourth quarter. Jump Financial LLC now owns 162,250 shares of the company's stock worth $573,000 after acquiring an additional 150,659 shares during the period.  Finally, Price T Rowe Associates Inc. MD boosted its holdings in  ADC Therapeutics by 25.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,750 shares of the company's stock valued at $166,000 after acquiring an additional 9,537 shares during the last quarter. 41.10% of the stock is currently owned by institutional investors and hedge funds. </p><h2>ADC Therapeutics Stock Performance</h2><p>NYSE ADCT opened at $4.07 on Wednesday. The firm's fifty day moving average price is $3.82 and its two-hundred day moving average price is $3.83. The stock has a market cap of $504.44 million, a PE ratio of -2.81 and a beta of 1.92. ADC Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $4.80. </p><h2>ADC Therapeutics Company Profile</h2> (Get Free Report)<p>ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.  </p><p>At the core of ADC Therapeutics' portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.</p><h2>Read More</h2><ul><li>Five stocks we like better than ADC Therapeutics</li><li>New Copper-Rich “Kraken” Zone Discovered</li><li>Silver Is the New Oil—And the World’s Running Dry</li><li>America’s 1776 happening again</li><li>3 Signs You May Want to Switch Financial Advisors</li><li>Silver's squeeze is tightening - opportunity forming</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFEQ1Q?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFEQ1Q"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ADC Therapeutics Right Now?</h2><p>Before you consider ADC Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADC Therapeutics wasn't on the list.</p><p>While ADC Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IBBQ

ADCT

<p>ADC Therapeutics SA (NYSE:ADCT) has received a consensus rating of "Moderate Buy" from five analysts, with one sell rating and four buy ratings. The average 12-month price target is $7.33. Recent reports include Wall Street Zen upgrading to "hold" and Guggenheim setting a $10 target. Institutional investors own 41.10% of the stock. ADC Therapeutics focuses on developing antibody-drug conjugates for hematological malignancies, with a market cap of $504.44 million and a current stock price of $4.07.</p>

Market Beat

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

ADC Therapeutics SA

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

VG Health

iShares Biotechnology ETF

ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Moderate Buy" from Brokerages